1 results match your criteria: "and his Ph.D. from the Massachusetts Institute of Technology.[Affiliation]"
Implementation of a Market Entry Reward within the United States.
J Law Med Ethics
June 2018
Gregory W. Daniel, Ph.D., M.P.H., R.Ph., is the Deputy Director of the Robert J. Margolis, MD, Center for Health Policy and a Clinical Professor in the Fuqua School of Business at Duke University. He received his B.S. in Pharmacy, M.S. in Pharmaceutical Administration, and M.P.H. in Biostatistics from the Ohio State University and his Ph.D. in Pharmaceutical Economics, Policy, and Outcomes from the University of Arizona. Monika Schneider, Ph.D., is a Research Associate at the Robert J. Margolis, MD, Center for Health Policy at Duke University. She received her B.S. in Biological Sciences from Butler University and her Ph.D. in Microbiology and Immunology at the University of North Carolina, Chapel Hill. Marianne Hamilton Lopez, Ph.D., is a Research Director at the Robert J. Margolis, MD, Center for Health Policy at Duke University. She received her B.A. in Politics and Women's Studies from Earlham College, her M.P.A. from the George Washington University, and her Ph.D. in Public Policy from the University of Maryland, Baltimore County. Mark B. McClellan, M.D., Ph.D., is the Director of the Robert J. Margolis, MD, Center for Health Policy and the Robert J. Margolis, MD, Professor of Business, Medicine and Policy, with appointments as Professor of the Practice of Business Administration in the Fuqua School of Business and Professor of the Practice in the Sanford School of Public Policy at Duke University. He received his B.A. at the University of Texas, Austin, his M.P.A. from Harvard University, his M.D. from the Harvard-MIT Division of Health Sciences and Technology, and his Ph.D. from the Massachusetts Institute of Technology.
As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to "value-based" payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.
View Article and Find Full Text PDF